Sign in
First Results From a Phase 1B Multiple-Dose Study of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate (ABC) With Extended Durability
Pravin U. Dugel, MD
Annual Meeting Talks
2019
Outcomes of Anti-VEGF Treatment for CNV in Fellow Eyes of Previously Treated Patients with Wet AMD
Tarek S. Hassan, MD, FASRS
Updates from the Field
What Do the HARBOR Data Reveal About the Relationship Between the Drying of Subretinal and Intraretinal Fluid and Associated Vision Outcomes?
Nancy M. Holekamp, MD, FASRS
Category: Pharmacology-AntiVEGF